Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
Fecal incontinence after moderately hypofractionated volumetric modulated arc therapy for prostate cancer: incidence and impact on quality of life.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lozano Joan, Feltes Nicolas, Colomer Montserrat, Lizondo Maria, Carmona Mamen, Romero Clara, Ribas Yolanda, Paredes Saturio, Galdeano Manuel, Solé Josep Maria
Аннотация
PURPOSE: Fecal incontinence (FI) is a late toxicity consequence in prostate cancer patients treated with current radiotherapy schedules that remains poorly described and understood. The main objective of this work is to describe the incidence of appearance of FI in these patients, and to analyze whether this late radiotoxicity event affects the quality of life of survivors.
METHODS: Prospective follow-up study was performed on a cohort of 91 patients with non-metastatic prostate cancer undergoing moderately hypofractionated volumetric modulated arc therapy (VMAT at 2.5-3 Gy/session) with image-guided radiotherapy (IGRT) in a real-world clinical practice scenario. The incidence of FI (using the Vaizey score) and FI-free survival time after completion of radiotherapy were presented. We additionally assessed the scores on the FI Quality of Life (FIQL) scale in both patients with and without FI.
RESULTS: Within 2 years after radiotherapy, 10 of 91 patients (11%) showed some degree of FI with an average onset at 13.59 months. Patients with some degree of FI had worse FIQL scores than those without FI (p < 0.001).
CONCLUSION: Patients with localized prostate cancer treated with moderately hypofractionated VMAT/IGRT had a significant incidence of fecal incontinence, which negatively affected the quality of life of survivors.
TRIAL REGISTRY: The study protocol was registered on clinicaltrials.gov (NCT04262609) on 5 February 2020.
METHODS: Prospective follow-up study was performed on a cohort of 91 patients with non-metastatic prostate cancer undergoing moderately hypofractionated volumetric modulated arc therapy (VMAT at 2.5-3 Gy/session) with image-guided radiotherapy (IGRT) in a real-world clinical practice scenario. The incidence of FI (using the Vaizey score) and FI-free survival time after completion of radiotherapy were presented. We additionally assessed the scores on the FI Quality of Life (FIQL) scale in both patients with and without FI.
RESULTS: Within 2 years after radiotherapy, 10 of 91 patients (11%) showed some degree of FI with an average onset at 13.59 months. Patients with some degree of FI had worse FIQL scores than those without FI (p < 0.001).
CONCLUSION: Patients with localized prostate cancer treated with moderately hypofractionated VMAT/IGRT had a significant incidence of fecal incontinence, which negatively affected the quality of life of survivors.
TRIAL REGISTRY: The study protocol was registered on clinicaltrials.gov (NCT04262609) on 5 February 2020.